Gilead Sciences disappoints, as 1st-qtr sales and profits plunge

3 May 2017

US biotech major Gilead Sciences (Nasdaq: GILD) posted first quarter 2017 financial results that missed analysts’ expectations, with both sales and earnings showing marked declines. Gilead shares fell 2.17% to $67.10 in pre-market trading today.

Total revenues for the quarter were down 16.4% at $6.51 billion, falling short of Wall Street's consensus $6.63 billion expectations for the quarter. Net income was $2.7 billion or $2.05 per diluted share compared to $3.6 billion or $2.53 per diluted share in 2016.

Non-GAAP net income, which excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $2.9 billion or $2.23 per diluted share in 2017 compared to $4.3 billion or $3.03 per diluted share in 2016, both well below the average Wall Street forecast for adjusted EPS of $2.28 and revenues of $6.62 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK